BioXcel Therapeutics (BTAI) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 14, 2019 7:00 AM ESTKey data readouts expected for BXCL501 in 1H 2020including results of pivotal Phase 3 trialswith cash position sufficient through completion of studies
Phase 1b/2 trial for geriatric dementia/Alzheimers patients on track to readout in 1H 2020
Safety data readouts expected for BXCL701 Phase 1b/2 trial in treatment emergent Neuroendocrine Prostate Cancer (tNEPC) in Q4 2019; efficacy data readouts expected in 1H 2020
NEW HAVEN, Conn.--(BUSINESS WIRE)-- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence... More
